Get the Stockscreener App
12.14
1.76%
0.21
After Hours:
12.14
Korro Bio Inc stock is traded at $12.14, with a volume of 97,911.
It is up +1.76% in the last 24 hours and up +13.14% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$11.93
Open:
$11.96
24h Volume:
97,911
Relative Volume:
0.34
Market Cap:
$114.33M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-1.1979
EPS:
-10.1344
Net Cash Flow:
$-82.84M
1W Performance:
+8.06%
1M Performance:
+13.14%
6M Performance:
-39.51%
1Y Performance:
-54.45%
1-Day Range:
$11.85
$12.46
1-Week Range:
$10.90
$12.54
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
12.14 | 112.35M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio, Inc. CEO Ram Aiyar to Present at TD Cowen 46th Annual Health Care Conference - Quiver Quantitative
RNA medicine developer Korro to present at three-day Boston health conference - Stock Titan
Trend Report: What is Origin Agritech Limiteds revenue forecast2025 Market Outlook & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Merger Talk: Is Korro Bio Inc exposed to political riskJuly 2025 Sentiment & Capital Efficient Trading Techniques - baoquankhu1.vn
Will Korro Bio Inc stock recover after earningsTrade Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Can Korro Bio Inc. be recession proofQuarterly Trade Report & Long-Term Safe Return Strategies - mfd.ru
Clear Street upgrades Korro Bio stock rating on hyperammonemia program potential - Investing.com South Africa
This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
KRRO Receives Upgraded Analyst Rating and Price Target Boost fro - GuruFocus
KRRO Receives Upgraded Analyst Rating and Price Target Boost from Clear Street | KRRO Stock News - GuruFocus
Clear Street Upgrades Korro Bio (KRRO) - Nasdaq
William Blair Upgrades Korro Bio (KRRO) - Nasdaq
Korro Bio Shares Rise After William Blair Upgrade - marketscreener.com
Korro Bio (NASDAQ:KRRO) Upgraded to "Outperform" at William Blair - MarketBeat
Is Korro Bio Inc. stock a value trapJuly 2025 Levels & Low Risk Investment Opportunities - mfd.ru
Is Korro Bio Inc. stock a good dividend stockQuarterly Investment Review & AI Powered Buy and Sell Recommendations - mfd.ru
We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully - Yahoo Finance
Can Korro Bio Inc. disrupt its industryMarket Growth Summary & Weekly Market Pulse Updates - mfd.ru
Korro Bio enhances executive compensation and retention incentives - MSN
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of "Hold" by Brokerages - MarketBeat
H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO) - MSN
Is FHN.PRB stock a good pick for beginnersJuly 2025 Analyst Calls & Precise Entry and Exit Recommendations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Korro Bio (KRRO) and AstraZeneca (AZN) - The Globe and Mail
HC Wainwright Brokers Lower Earnings Estimates for Korro Bio - Defense World
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? - Nasdaq
Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE - Yahoo Finance
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential By Investing.com - Investing.com Nigeria
Korro Bio's KRRO-121 Receives Strong Analyst Upgrades - intellectia.ai
Korro Bio Shares Rise After Piper Sandler, HC Wainwright Upgrades - marketscreener.com
KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism? - Stocktwits
Korro Bio stock rating upgraded by H.C. Wainwright to Buy on new drug potential - Investing.com Canada
Piper Sandler Upgrades Korro Bio to Overweight From Neutral, Adjusts Price Target to $30 From $11 - marketscreener.com
HC Wainwright Upgrades Korro Bio to Buy From Neutral, Price Target is $20 - marketscreener.com
This Fortinet Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
HC Wainwright & Co. Upgrades Korro Bio (KRRO) - Nasdaq
KRRO Shares Jump 13% On Analyst UpgradesWhat's Driving The Optimism? - Mena FN
Piper Sandler upgrades Korro Bio stock rating to Overweight on UCD treatment - Investing.com Nigeria
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential - Investing.com India
Oppenheimer Upgrades Korro Bio (KRRO) - Nasdaq
Korro Bio Shares Rise After Oppenheimer Upgrade - marketscreener.com
Raymond James reiterates Market Perform rating on Korro Bio stock By Investing.com - Investing.com India
Cantor Fitzgerald Upgrades Korro Bio to Overweight From Neutral - marketscreener.com
William Blair reiterates Market Perform rating on Korro Bio stock By Investing.com - Investing.com Canada
Raymond James reiterates Market Perform rating on Korro Bio stock - Investing.com
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):